You are quite right part of that sentence.
Go read the FDA statistical guidance in regards to approving drugs including difficult to treat indications with low Soc. Then compare that to your beloved imugene trials. The FDA is very strict on this.
Maybe future trials are going to improve so the FDA takes it seriously?
Many try, all the way up to the front gates. Only to be told to start again.
here’s an example of what they are looking for. Recommend trying to understand this and then compare it
https://www.targetedonc.com/view/fda-considers-approval-application-for-nivolumab-plus-ipilimumab-with-chemotherapy-for-unresectable-advanced-escc
Ann: S&P DJI Announces December 2021 Quarterly Rebalance, page-60
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.003(6.82%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.4¢ | 4.1¢ | $1.607M | 38.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 4542680 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 1675759 | 9 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |